This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A look at potential of acoramidis following the failure on Part A of the ATTRibute-CM study

Ticker(s): BBIO, PFE

Who's the expert?

Institution: University of Colorado
  • Director of Cardiac Amyloidosis & Cardiac Transplantation program and Associate Professor, Medicine-Cardiology at the University of Colorado. 
  • Currently manages ~60 active ATTR cardiac amyloid patients and has prescribed Tafamidis.
  • Research focuses on Cardiac Amyloidosis, Advanced Heart Failure, Cardiac Transplantation, and Mechanical Circulatory Support / Ventricular Assist Devices; has participated in multiple clinical trials investigating new pharmacologic and device therapies for patients with advanced heart failure and cardiac amyloidosis. 

Interview Questions

Roughly how many patients with amyloidosis do you currently manage?

Added By: user1ae2bf5f

What are your thoughts on the anti-wt and mt amyloid ATTR antibody approach for this indication? Is there space in the treatment paradigm for these types of approach?

Added By: user5d2d4f30

Alnylam's Onpattro is also being studied for use in this population. How do you that agent being used in your practice for the cm population?

Added By: mattiw2002

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.